Translation of the instructions can be
POTASSIUM Orotate tablets 500 mg
Instruction
For medical use of the medicinal product
Potassium orotate
Composition:
Active ingredient: potassium orotate;
1 tablet contains potassium orotate 500 mg;
excipients: lactose monohydrate; gelatin; stearic acid; potato starch.
Dosage form.
Pills.
Main physicochemical properties: solid, regular, round cylinders, the upper and lower surfaces of which are flat, the edges of the surfaces are beveled, with a dividing line, white in color.
Pharmacotherapeutic group.
Anabolic agents for systemic use. non-steroidal anabolic agents.
PBX code A14B.
Pharmacological properties.
Pharmacodynamics.
Potassium orotate has a general stimulating effect on metabolic processes, participates in protein and carbohydrate metabolism. The main structural element of potassium orotate is orotic acid.
Orotic acid ensures the synthesis of pyrimidine bases (uracil, thiamine, cytosine) in the process of nucleic acid synthesis, which are involved in the synthesis of protein molecules. As a result of its participation in carbohydrate metabolism, orotic acid normalizes galactose metabolism.
Potassium orotate as an anabolic agent is used to restore protein metabolism disorders and stimulate metabolic processes.
Pharmacokinetics.
Not studied.
Clinical characteristics.
Indication.
Comprehensive therapy of liver and biliary tract diseases caused by acute and chronic intoxications (except liver cirrhosis with ascites), myocardial dystrophy, myocardial infarction, chronic heart failure stage II-III, arrhythmias (extrasystoles), alimentary and alimentary-infectious hypotrophy in children, progressive muscular dystrophy, anemia, galactosemia, dermatoses.
It is also used during increased physical exertion and during the recovery period after serious illnesses.
Contraindication.
Hypersensitivity to the active substance and to other components of the drug. cirrhosis of the liver with ascites, acute and severe chronic renal failure, lymphogranulomatosis, malignant diseases of the hematopoietic organs, hyperkalemia.
Interaction with other drugs and other types of interactions.
The effectiveness of potassium orotate is increased when used simultaneously with folic acid and cyanocobalamin.
Potassium orotate improves the tolerability of cardiac glycosides (e.g. digoxin, celanide).
With simultaneous use with potassium-sparing diuretics and angiotensin-converting enzyme (ACE) inhibitors, the development of hyperkalemia is possible.
The drug can be used simultaneously with vitamins and cardiotonic drugs.
Astringents and enveloping agents (e.g. de-nol, sucralfate, algeldrat, magnesium hydroxide, bismuth preparations) may slightly reduce the absorption of potassium orotate in the digestive tract.
When used simultaneously with glucocorticosteroids, insulin, muscle relaxants, and oral contraceptives, the effectiveness of orotic acid decreases.
Application features.
Potassium orotate should not be used for potassium replacement therapy.
Potassium orotate should not be used during meals due to the possibility of its interaction with food components.
The drug contains lactose, therefore its use is contraindicated in patients with rare hereditary conditions such as galactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Use during pregnancy or breastfeeding.
The use of the drug during pregnancy is possible only when the expected benefit to the mother outweighs the potential risk to the fetus.
If necessary, use of the drug should stop breastfeeding.
The ability to influence the reaction speed when driving vehicles or other mechanisms.
Does not affect.
Method of administration and doses.
Potassium orotate is taken orally 1 hour before meals or 4 hours after meals. The tablets are swallowed without chewing, washed down with 150-200 ml of water.
Adults are prescribed 250-500 mg 2-3 times a day. The daily dose is 0.5 mg - 1.5 g. In some cases, if necessary, to increase the therapeutic effect, the daily dose for adults is increased to 3 g.
The course of treatment is 3-5 weeks, if necessary, the course of treatment is repeated after a month.
Children from 5 years of age are prescribed potassium orotate in a daily dose of 10-20 mg/kg of body weight. This daily dose is divided into 2-3 doses.
Children.
Not recommended for use in children under 5 years of age.
Overdose.
With prolonged use, allergic dermatoses are observed, which requires desensitization therapy; hyperkalemia, which requires discontinuation of the drug.
If used in high doses while following a low-protein diet, liver dystrophy may develop, requiring discontinuation of the drug and appropriate therapy.
Possible increased side effects.
Adverse reactions.
The drug is usually well tolerated. In isolated cases, allergic reactions (including dermatitis, skin rashes) and dyspeptic reactions (including nausea, vomiting, diarrhea) are possible, which quickly resolve upon discontinuation of the drug.
Hyperkalemia may develop, accompanied by paresthesias and changes in ECG parameters.
Expiration date.
4 years.
Storage conditions.
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children.
Packaging.
10 tablets in blisters.
Vacation category.
Without a prescription.
Producer.
PJSC Lubnyfarm.
Location of the manufacturer and address of its place of business.
Ukraine, 37500, Poltava region, M lubny, Barvinkovy St., 16.
